Etaracizumab

• CAT Number: I042423
• CAS Number: 892553-42-3
• Molecular Weight: 144.3 (kDa)
• Purity: ≥95%

Etaracizumab (Cat No.: I042423) is a humanized monoclonal antibody that targets integrin αvβ3, a receptor involved in angiogenesis, tumor growth, and metastasis. By binding to αvβ3, etaracizumab inhibits endothelial cell adhesion and migration, disrupting the formation of new blood vessels that tumors require for growth. It has been evaluated in clinical trials for treating cancers such as melanoma and glioblastoma. Etaracizumab is also studied for its potential to enhance the effects of chemotherapy and radiation by impairing tumor vascular support.

Reference

[1]. Hersey P, et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or – dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010 Mar 15;116(6):1526-34.
[Content Brief]